Pliant Therapeutics

PLRX · NASDAQ

$0.9124+$0.0137 (+1.52%)TodayMarket closed · Oct 20, 4:27 PM ET

Prev close $0.8987

About PLRX

Pliant Therapeutics, Inc. engages in the discovery, development and commercialization of therapies for fibrotic diseases. The company is headquartered in South San Francisco, California and currently employs 49 full-time employees. The company went IPO on 2020-06-03. The Company’s lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of avb6 and avb1 integrins that is in development in the lead indication for the treatment of idiopathic pulmonary fibrosis, or idiopathic pulmonary fibrosis (IPF). The Company’s second clinical program, PLN-101095, is a small molecule, dual selective inhibitor of integrins avb8 and avb1 for the treatment of solid tumors that are resistant to immune checkpoint inhibitors. Its Phase 1-ready program PLN-101325, is in development for treatment of muscular dystrophies, including Duchenne muscular dystrophy. PLN-101325 is a monoclonal antibody designed to act as an allosteric agonist of integrin a7b1.

Employees: 49
Headquarters: South San Francisco, California
Listed: Jun 3, 2020
Sector: Health Care
Industry: Pharmaceuticals
Website: pliantrx.com

Leadership

Pliant Therapeutics executives
Name	Title	Since	Age
Hoyoung Huh	—	—	55
Bernard Coulie	—	2016	59
Keith Cummings	—	—	48
Minnie Kuo	—	—	45
Lily Cheung	—	—	52
Delphine Imbert	—	—	—
Suzanne Bruhn	—	—	61
Darren Cline	—	—	60
Gayle Crowell	—	—	74
John Curnutte	—	—	73
Katharine Knobil	—	—	61
Steven Krognes	—	—	56
Thomas Mccourt	—	—	67
David Pyott	—	—	72
Christopher Keenan	—	—	—

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

Pliant Therapeutics suppliers and customers
Company	Relationship	Country	Correlation
Novartis NOVN.SW	Supplier and customer	CH	0.13
Adimab, LLC	Supplier and customer	US	—

Similar companies

Companies in the same industry as Pliant Therapeutics

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.